Terns Pharmaceuticals Inc. (USA and Shanghai) announced on 23 July, 2020, the initiation of patient dosing in the Phase2A study (LIFT study) of TERN-101 in development for NASH.

TERN-101 is FXR agonist. This compound is a non-bile acid FXR agonist unlike Intercept's FXR agonist (OCA), which was recently dropped, and is expected to have no side effects when administered to NASH patients. We are waiting for future clinical results to be reported.

For detailed information, see the below URL.

https://www.ternspharma.com/7-22-20-terns-announces-initiation-of-patient-dosing-in-lift-study